Pyrimidine hydrazide compounds as PGDS inhibitors

US8258130B2 · kind B2 · utility

Assignee

• Sanofi · FR

Inventors

• Suzanne C. Aldous · Gillette, US
• Michael W Fennie · East Stroudsburg, US
• John Ziqi Jiang · Fryeburg, US
• Stanly John · Bound Brook, US
• Lan Mu · Berkeley Heights, US
• Brian Pedgrift · Morristown, US
• James Pribish · Piscataway, US
• Barbara S. Rauckman · Flemington, US
• Jeffrey S. Sabol · Loveland, US
• Grzegorz T Stoklosa · Fryeburg, US
• Sukanthini Thurairatnam · Bedminster, US
• Christopher L. VANDEUSEN · Hopkinton, US

Key dates

• Filing date: Sep 30, 2009
• Grant date: Sep 4, 2012
• Expiry date: Sep 8, 2030

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D417/14
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

This invention is directed to a compound of formula (I):wherein R1, R2, R3, R4 and L1 are as defined herein, a pharmaceutical composition comprising the compound, and the use of the compound to treat allergic and/or inflammatory disorders, particularly disorders such as allergic rhinitis, asthma and/or chronic obstructive pulmonary disease (COPD).